SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is a top trending stock following its earnings report, which, despite beating estimates, has been overshadowed by concerns regarding the Warner Bros Discovery acquisition. The community is sharply divided, with bulls viewing the current dip as an oversold opportunity for long-term content expansion, while bears cite the deal's cost, debt implications, and paused share buybacks as reasons for further downside. This strategic move and its perceived impact on future margins are driving intense discussion and significant price action.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network ($BNAI) is experiencing significant market attention following news of a strategic AI licensing partnership in Africa, including a pilot program with Nelson Mandela University. This development, combined with discussions around a reportedly thin float and high short interest, is driving substantial pre-market volatility and community speculation about a potential short squeeze. Traders are actively monitoring for sustained momentum, positioning BNAI as a key focus within the AI sector narrative.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical (DRTS) is trending with immense community excitement, primarily driven by the high anticipation of potential PMDA Japan approval for its Alpha DaRT therapy, following compelling pancreatic cancer data. Investors are increasingly bullish, viewing recent strong clinical updates and growing institutional interest as key catalysts for this innovative oncology technology, which many believe is poised for significant recognition.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amid intense market focus on an upcoming high-profile address and recent geopolitical rhetoric, particularly concerning Greenland and global trade. The community is sharply divided, with many anticipating a quick market rebound while others brace for further downside, linking market direction to these unfolding events. This dynamic fuels significant volatility as participants actively debate the broader implications for the economy.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is experiencing a parabolic rally to new record highs, driven by escalating global trade tensions and broad geopolitical uncertainty. The community is actively discussing gold's role as a safe haven amidst concerns over sovereign debt, potential currency debasement, and central bank diversification, fueling significant short-covering and strong bullish momentum.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is experiencing significant volatility and declines as natural gas futures surge dramatically, driven by widespread "Arctic Blast" weather forecasts across the US. This rapid price action is causing extreme pressure for many traders, leading to discussions of a "widowmaker" market as some cautiously "buy the dip" on KOLD while others are caught in the squeeze.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending as President Trump's aggressive rhetoric regarding Greenland and potential new tariffs, coupled with concerns over Japan's bond market, fuels a broad market sell-off. The community is sharply divided, with many anticipating further declines and a retest of crucial support levels, while others expect an eventual 'buy the dip' recovery, viewing current fears as an overreaction.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending due to overwhelmingly positive Phase 1 clinical trial results for its atopic dermatitis drug, soquelitinib, demonstrating strong efficacy and a favorable safety profile even in treatment-resistant patients. This promising early data has ignited bullish sentiment about its blockbuster potential and possible short squeeze, despite community concerns surrounding a recently announced public offering to fund future trials.

Hycroft Mining Holding Corp. engages in the exploration, mining, and development of gold and silver properties. The company was founded on August 28, 2017 and is headquartered in Winnemucca, NV.

Hycroft Mining Holding Corporation - Ordinary Shares - Class A

Hycroft Mining Holding Corp

Hycroft Mining is trending due to reports of exceptionally high-grade silver drill results across its vast land, significantly boosting optimism for future production. The community is actively discussing continuous insider buying by Eric Sprott and surging precious metal prices as catalysts for substantial upside, while also considering the company's non-producing status and potential for dilution. This confluence of factors, coupled with discussions of a possible short squeeze and growing silver demand, is driving intense conversation around the mining company.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is experiencing heightened volatility and intense discussion, largely influenced by President Trump's remarks at the Davos World Economic Forum and ongoing geopolitical tensions. The community remains deeply divided, with many bears highlighting significant drops and questioning Bitcoin's safe-haven status amidst rising gold prices, while bulls emphasize strong accumulation by institutional players and technical indicators pointing to a potential rebound from leveraged short attacks.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;</li><li>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment.</li><li>Test volumes climbed to 18,000 in Q4 and 62,600 for the year.</li></ul>Biodesix Inc. (BDSX) stock surged over 23% in Monday’s premarket after the Colorado-based diagnostics firm provided a strong outlook for the fourth quarter (Q4) and fiscal year 2025.&nbsp;The company expects Q4 revenue of $28.8 million, a 41% year-over-year (YoY) increase, while full-year revenue is estimated at $88.5 million, up 24% YoY. The outlook for Q4 and FY2025 exceeds the analyst consensus estimate of $24.95 million and $84.65 million, respectively, according to Fiscal AI data.&nbsp;<h2 class="st-heading-2">Growth Driven By Lung Diagnostics</h2>Biodesix said revenue gains were largely fueled by the company’s lung diagnostics segment, which is estimated to have generated $25.2 million in Q4 and $79.2 million for the full year. The results reflect a 47% and 22% YoY increase, respectively.&nbsp;Test volumes climbed to 18,000 in Q4 and 62,600 for the year, rising 23% and 15% from the previous year. The increase was driven by higher test volumes, stronger revenue per test, and about $1 million in collections from older claims.&nbsp;<blockquote>“Biodesix finished 2025 with a strong fourth quarter, delivering full year estimated revenue of $88.5 million, exceeding the top end of our increased guidance of $84-$86 million.”-Scott Hutton, CEO, Biodesix</blockquote>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/BDSX">Biodesix stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_12_084117_png_27b632f1b5.webp" alt="BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits" width="931" height="98"><figcaption>BDSX’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Jan. 12, 2026 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Development Services&nbsp;</h2>The company’s development services segment contributed an estimated $3.6 million in Q4 and $9.3 million for 2025, representing growth of 13% and 41% over the prior year, respectively.&nbsp;“Based on our strong revenue flow-through and operating leverage, we are affirming our expectation of positive Adjusted EBITDA in the fourth quarter,” added Hutton.&nbsp;Biodesix said it ended 2025 with $19.0 million in cash and cash equivalents, a 14% increase over the previous quarter.&nbsp;BDSX stock declined by over 77% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/apple-captures-20-of-global-smartphone-market/cmU96DMR4E4">Apple Captures 20% Of Global Smartphone Market, But Rising Memory Costs Cast Shadow On 2026 Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Biodesix logo is seen displayed on a smartphone screen.

BDSX Stock Shot Up 23% Pre-Market Today — What’s Fueling The Surge? 

The company expects Q4 revenue of $28.8 million, a 41% year-over-year increase, while full-year revenue is estimated at $88.5 million, up 24% year-over-year.

This Diagnostics Stock Is Surging 23% Pre-Market Today – Here’s Why 

Equity

Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Inside the Recent Strength in Biotech ETFs 

Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.



2 ETFs to Watch for Outsized Volume on Biotechnology Stocks 

Biotech ETFs PBE and FBT saw trading volumes soar to over four times their averages, signaling rising interest amid a down day for major indexes.  

Bitcoin (BTC) dropped below $114,000 in&nbsp;pre-market U.S. hours on Wednesday, while Ripple’s native token (XRP), Solana (SOL), Cardano (ADA), and Dogecoin (DOGE) led the slide among&nbsp;other major tokens.The overall cryptocurrency market slipped around 1.3% over the past day, with the overall&nbsp;market capitalization slipping below $3.8 trillion.&nbsp;<a href="http://stocktwits.com/symbol/BTC.X">Bitcoin’s price</a> fell 0.7% in the last 24 hours, while retail sentiment on Stocktwits moved lower in&nbsp;the ‘bearish’ territory. Bitcoin’s current price is 7.2% below its all-time high of over $122,000, seen last month.&nbsp;<a href="http://stocktwits.com/symbol/XRP.X">XRP’s price</a> was down 4.4% and&nbsp;<a href="http://stocktwits.com/symbol/ADA.x">Cardano’s price</a> slipped around 3.9% in pre-market U.S. hours.<a href="https://stocktwits.com/symbol/ETH.X">Ethereum price</a> fell 1.7% in the last 24 hours, still above $3,600. On Stocktwits, retail sentiment around Ethereum remained in ‘bearish’ territory over the past day.&nbsp;<a href="https://stocktwits.com/symbol/SOL.X">Solana’s price</a> fell 4.2% and&nbsp;<a href="https://stocktwits.com/symbol/DOGE.X">Dogecoin’s price</a> dipped 3.6% over the past day.&nbsp;Weakness in the cryptocurrency market&nbsp;persisted as investors continued to withdraw money from U.S.-listed spot Bitcoin exchange-traded funds (ETFs). According to&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://sosovalue.com/assets/etf/us-btc-spot">data</a> from SoSoValue, the daily total net outflow amounted to $196.18 million on Tuesday, with Fidelity’s FBTC (FBTC) and BlackRock’s IBIT (IBIT) accounting for the biggest shares.&nbsp;This is the fourth day of outflows from U.S.-listed spot BTC ETFs, the longest streak since April. More than $114 million was withdrawn on Thursday, followed by $812 million on Friday and $333 million on Monday.Amid a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://blog.coinshares.com/volume-245-digital-asset-fund-flows-weekly-report-e4ac31e2961a">choppy week</a> of ETF flows, $298 million worth of crypto was liquidated over the past day, according to Coinglass&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.coinglass.com/LiquidationData">data</a>. Long liquidations were around $210 million, while short liquidations totaled $87 million. Ethereum experienced the largest liquidations of $89 million, followed by Bitcoin at $43 million.Crypto-linked stocks were in the doldrums during pre-market trade on Wednesday. Shares of Strategy (MSTR), the largest corporate holder of Bitcoin, edged 0.7% higher. Bitcoin miner Riot Platforms (RIOT) stock edged 0.09% higher, and shares of its peer, Mara Holdings (MARA), gained 0.06%. Crypto exchange Coinbase Global’s (COIN) shares were up 1.2% in pre-market trade.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ray-dalio-warns-of-fiat-trust-breakdown-says-gold-standard-return-is-possible/chrLMkxRd20">Ray Dalio Warns Of Fiat Trust Breakdown, Says Gold Standard Return Is Possible</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A neon sign advertises a Bitcoin and Ethereum crypto currency exchange in Warsaw, Poland, on January 4, 2025.

Bitcoin Drops Below $114K With XRP, Solana, Dogecoin Leading The Slide – ETF Outflows Hit $1.3B Over the Last 4 Days

Weakness in the cryptocurrency market remained as investors continued to withdraw money from U.S.-listed spot Bitcoin exchange-traded funds.

Cryptocurrency

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Nasdaq-listed American Depository Receipts (ADRs) of Genmab A/S (GMAB) rose over 1% on Thursday morning after Johnson &amp; Johnson (JNJ)<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/04/15/3061529/0/en/Genmab-Announces-Net-Sales-of-DARZALEX-daratumumab-for-First-Quarter-of-2025.html"> announced</a> that sales of the oncology drug Darzalex rose over 20% in the first quarter of 2025.Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&amp;J's exclusive worldwide license to develop, manufacture, and commercialize daratumumab.Genmab licensed daratumumab to Johnson &amp; Johnson unit Janssen Biotech, Inc. in August 2012.Darzalex is a prescription medication used to treat multiple myeloma, a type of blood cancer. For the three months through the end of March, Johnson &amp; Johnson reported sales of $3.24 billion for Darzalex, marking a growth of 20.3% year-on-year.Darzalex accounted for over 23% of the company’s overall sales in its innovative medicine segment and nearly 15% of its overall reported sales.Darzalex sales in the U.S. jumped 25% to $1.83 billion during the quarter, while sales outside the country jumped 15% to $1.41 billion.The rise in Darzalex sales enabled the company to offset the 34% drop in sales of its immunology drug Stelara to $1.63 billion.On Stocktwits, retail sentiment around Genmab fell marginally while staying within ‘extremely bullish’ territory over the past 24 hours, while message volume dropped to ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:645/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_15_at_9_35_32_AM_png_f443284110.webp" alt="GMAB's Sentiment Meter and Message Volume as of 9:35 a.m. ET on April 14, 2025 | Source: Stocktwits" width="645" height="149"><figcaption>GMAB's Sentiment Meter and Message Volume as of 9:35 a.m. ET on April 14, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that Genmab shares are cheap.<a href="https://stocktwits.com/Pika_Capital/message/611668890">https://stocktwits.com/Pika_Capital/message/611668890</a><a href="https://stocktwits.com/symbol/GMAB">GMAB stock</a> fell by about 7% year-to-date and over 33% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/dow-jones-futures-tick-higher-as-investors-await-earnings-monitor-tariff-developments/chQRaHyRbau">Dow Jones Futures Tick Higher As Investors Await Earnings, Monitor Tariff Developments</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Global stock market chart and trading board - stock photo

Genmab Stock Rises On Strong Darzalex Sales In Q1: Retail Remains Extremely Bullish

Genmab receives royalties on the worldwide net sales of Darzalex, both the intravenous and subcutaneous products, under J&J's exclusive worldwide license to develop, manufacture, and commercialize daratumumab. 

First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

FBT
First Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund

Feed

News

Sentiment

Fundamentals

Info

Latest FBT News

FBTFirst Trust Exchange-Traded Fund III - First Trust NYSE Arca Biotechnology Index Fund